The Influence of Nonfatal Cardiac Events on Late Survival
نویسندگان
چکیده
Background—The Warm Heart Trial randomized 1732 CABG patients to receive warm or cold blood cardioplegia. In the warm cardioplegia patients, nonfatal perioperative cardiac events were significantly decreased and the mortality rate was nonsignificantly decreased (1.4% versus 2.5%, P50.12). The purpose of the present study was to evaluate the late results of these trial patients. Methods and Results—Randomization was stratified according to surgeon and urgency of the operation. Seven hundred sixty-two patients recruited from 1 of the centers were followed through the hospital clinic for late events. Late survival (including perioperative deaths) at 72 months was nonsignificantly greater in the warm cardioplegia patients (94.561.7%, mean6SEM) than in the cold cardioplegia patients (90.962.6%). Independent predictors of mortality by Cox proportional hazards model were redo CABG, diabetes mellitus, renal insufficiency, and increasing age. The influence of nonfatal perioperative events (perioperative myocardial infarction according to computerized ECG readings or low output syndrome as determined by an outcome committee) on late survival was also analyzed. Late survival at 84 months was significantly reduced in the group who experienced nonfatal perioperative outcomes (94.561.7% versus 84.964.5%, P,0.001) and remained a significant predictor after adjustment for other important variables (risk ratio 6.4, 95% CI 1.87 to 8.73, P,0.0001). Conclusions—Effective myocardial protection through either cold or warm blood cardioplegia is essential, because late survival is significantly reduced in patients with nonfatal perioperative cardiac outcomes. (Circulation. 2000;102[suppl III]:III-339-III-345.)
منابع مشابه
Late results of the Warm Heart Trial: the influence of nonfatal cardiac events on late survival.
BACKGROUND The Warm Heart Trial randomized 1732 CABG patients to receive warm or cold blood cardioplegia. In the warm cardioplegia patients, nonfatal perioperative cardiac events were significantly decreased and the mortality rate was nonsignificantly decreased (1. 4% versus 2.5%, P:=0.12). The purpose of the present study was to evaluate the late results of these trial patients. METHODS AND ...
متن کاملEffect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes.
BACKGROUND Although a raised plasma homocysteine is a risk factor for vascular disease, it is not known whether it is associated with an adverse cardiac outcome in patients admitted with acute coronary syndromes. We evaluated the relationship between plasma homocysteine and short-term (28 days) and long-term (median 2.5 years) prognosis in acute coronary syndromes. METHODS AND RESULTS We eval...
متن کاملRecurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study.
BACKGROUND Few population-based studies with long-term follow-up have compared risk of recurrent stroke and cardiac events after first ischemic stroke. The relative risk of these two outcomes may inform treatment decisions. METHODS In the population-based Northern Manhattan Study, first ischemic stroke patients age 40 or older were prospectively followed for recurrent stroke, myocardial infar...
متن کاملThe prognostic value of stress/rest gated myocardial perfusion SPECT in patients with known or suspected coronary artery disease
Introduction:Gated myocardial perfusion SPECT has diagnostic and prognostic values in coronary artery disease (CAD). We tried to determine prognostic values of the left ventricular perfusion & functional indices as well as transient left ventricular dilation (TID) derived from gated myocardial perfusion SPECT. Methods: 1820patients who underwent gated myo...
متن کاملRosuvastatin in diabetic hemodialysis patients.
A randomized, placebo-controlled trial in diabetic patients receiving hemodialysis showed no effect of atorvastatin on a composite cardiovascular endpoint, but analysis of the component cardiac endpoints suggested that atorvastatin may significantly reduce risk. Because the AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Car...
متن کامل